Final clinical and pharmacokinetic (PK) results from a phase 1 study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid tumors stratified according to N-cad expressionDavid J. Stewart, W. P. Peters, J. Maroun et al.|Journal of Clinical Oncology|2006Cited by 14
A phase I study of the novel molecularly targeted vascular targeting agent, Exherin (ADH-1), shows activity in some patients with refractory solid tumors stratified according to N-cadherin expressionDerek J. Jonker, W. P. Peters, David J. Stewart et al.|Journal of Clinical Oncology|2005Cited by 6